Literature DB >> 24668473

Sortilins in neurotrophic factor signaling.

S Glerup1, A Nykjaer, C B Vaegter.   

Abstract

The sortilin family of Vps10p-domain receptors includes sortilin, SorLA, and SorCS1-3. These type-I transmembrane receptors predominate in distinct neuronal tissues, but expression is also present in certain specialized non-neuronal cell populations including hepatocytes and cells of the immune system. The biology of sortilins is complex as they participate in both cell signaling and in intracellular protein sorting. Sortilins function physiologically in signaling by pro- and mature neurotrophins in neuronal viability and functionality. Recent genome-wide association studies have linked members to neurological disorders such as Alzheimer's disease and bipolar disorder and outside the nervous system to development of coronary artery disease and type-2 diabetes. Particularly well described are the receptor functions in neuronal signaling by pro- (proNT) and mature (NT) neurotrophins and in the processing/metabolism of amyloid precursor protein (APP).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668473     DOI: 10.1007/978-3-642-45106-5_7

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  9 in total

1.  SorCS2 is required for BDNF-dependent plasticity in the hippocampus.

Authors:  S Glerup; U Bolcho; S Mølgaard; S Bøggild; C B Vaegter; A H Smith; J L Nieto-Gonzalez; P L Ovesen; L F Pedersen; A N Fjorback; M Kjolby; H Login; M M Holm; O M Andersen; J R Nyengaard; T E Willnow; K Jensen; A Nykjaer
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

Review 2.  Retromer-Mediated Trafficking of Transmembrane Receptors and Transporters.

Authors:  Stine C Klinger; Piotr Siupka; Morten S Nielsen
Journal:  Membranes (Basel)       Date:  2015-07-06

Review 3.  Neurotrophins and their involvement in digestive cancers.

Authors:  Sabrina Blondy; Niki Christou; Valentin David; Mireille Verdier; Marie-Odile Jauberteau; Muriel Mathonnet; Aurélie Perraud
Journal:  Cell Death Dis       Date:  2019-02-11       Impact factor: 8.469

4.  Altered dopaminergic firing pattern and novelty response underlie ADHD-like behavior of SorCS2-deficient mice.

Authors:  Simon Glerup; Anders Nykjaer; Ditte Olsen; Niels Wellner; Mathias Kaas; Inge E M de Jong; Florence Sotty; Michael Didriksen
Journal:  Transl Psychiatry       Date:  2021-01-25       Impact factor: 6.222

5.  Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer.

Authors:  Sabrina Blondy; Hugo Talbot; Sofiane Saada; Niki Christou; Serge Battu; Julie Pannequin; Marie-Odile Jauberteau; Fabrice Lalloué; Mireille Verdier; Muriel Mathonnet; Aurélie Perraud
Journal:  J Cell Mol Med       Date:  2020-12-16       Impact factor: 5.310

6.  Single neonatal dexamethasone administration has long-lasting outcome on depressive-like behaviour, Bdnf, Nt-3, p75ngfr and sorting receptors (SorCS1-3) stress reactive expression.

Authors:  D A Lanshakov; E V Sukhareva; V V Bulygina; A V Bannova; E V Shaburova; T S Kalinina
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

Review 7.  Neurotensin pathway in digestive cancers and clinical applications: an overview.

Authors:  Niki Christou; Sabrina Blondy; Valentin David; Mireille Verdier; Fabrice Lalloué; Marie-Odile Jauberteau; Muriel Mathonnet; Aurélie Perraud
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

8.  Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF.

Authors:  H N Buttenschøn; D Demontis; M Kaas; B Elfving; S Mølgaard; C Gustafsen; L Kaerlev; C M Petersen; A D Børglum; O Mors; S Glerup
Journal:  Transl Psychiatry       Date:  2015-11-10       Impact factor: 6.222

Review 9.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.